Literature DB >> 33759136

Deficiency of natural anticoagulants: how should we manage cardiovascular prevention?

Francesco Paciullo1, Andrea Baccolo2.   

Abstract

Year:  2021        PMID： 33759136     DOI： 10.1007/s11739-021-02712-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  18 in total

1.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Authors:  G Ruiz-Irastorza; M J Cuadrado; I Ruiz-Arruza; R Brey; M Crowther; R Derksen; D Erkan; S Krilis; S Machin; V Pengo; S Pierangeli; M Tektonidou; M Khamashta
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

2.  Aspirin for Primary Prevention of Cardiovascular Events.

Authors:  Hesham K Abdelaziz; Marwan Saad; Naga Venkata K Pothineni; Michael Megaly; Rahul Potluri; Mohammed Saleh; David Lai Chin Kon; David H Roberts; Deepak L Bhatt; Herbert D Aronow; J Dawn Abbott; Jawahar L Mehta
Journal:  J Am Coll Cardiol       Date:  2019-06-18       Impact factor: 24.094

3.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen.

Authors:  Peter J Grant; Francesco Cosentino
Journal:  Eur Heart J       Date:  2019-10-14       Impact factor: 29.983

Review 4.  Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma.

Authors:  Paolo Gresele; Francesco Paciullo; Rino Migliacci
Journal:  Intern Emerg Med       Date:  2020-05-13       Impact factor: 3.397

Review 5.  Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review.

Authors:  Salik Nazir; Niranjan Tachamo; Saroj Lohani; Rittu Hingorani; Dilli R Poudel; Anthony Donato
Journal:  Coron Artery Dis       Date:  2017-06       Impact factor: 1.439

Review 6.  Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.

Authors:  Laurent Arnaud; Alexis Mathian; Hervé Devilliers; Amelia Ruffatti; Maria Tektonidou; Ricardo Forastiero; Vittorio Pengo; Marc Lambert; Guillaume Lefevre; Maria Angeles Martinez-Zamora; Juan Balasch; Denis Wahl; Zahir Amoura
Journal:  Autoimmun Rev       Date:  2014-10-22       Impact factor: 9.754

7.  Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

Authors:  Rolf T Urbanus; Bob Siegerink; Mark Roest; Frits R Rosendaal; Philip G de Groot; Ale Algra
Journal:  Lancet Neurol       Date:  2009-09-25       Impact factor: 44.182

Review 8.  Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.

Authors:  Laurent Arnaud; Alexis Mathian; Amelia Ruffatti; Doruk Erkan; Maria Tektonidou; Ricard Cervera; Ricardo Forastiero; Vittorio Pengo; Marc Lambert; Maria Angeles Martinez-Zamora; Juan Balasch; Stephane Zuily; Denis Wahl; Zahir Amoura
Journal:  Autoimmun Rev       Date:  2013-11-02       Impact factor: 9.754

9.  The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study.

Authors:  Daniela Tormene; Franco Noventa; Elena Campello; Sabrina Gavasso; Michelangelo Marobin; Giacomo Turatti; Paolo Prandoni; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

10.  Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Authors:  Georg Gelbenegger; Marek Postula; Ladislav Pecen; Sigrun Halvorsen; Maciej Lesiak; Christian Schoergenhofer; Bernd Jilma; Christian Hengstenberg; Jolanta M Siller-Matula
Journal:  BMC Med       Date:  2019-11-04       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.